The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

(2016) M. V. Maus et al.   CLINICAL CANCER RESEARCH

IFN  and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma

(2016) K. B. Long et al.   Cancer Discovery

Macrophage-derived nitric oxide initiates T-cell diapedesis and tumor rejection

(2016) Ibrahim M. Sektioglu et al.   OncoImmunology

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

(2015) Douglas Marvel et al.   JOURNAL OF CLINICAL INVESTIGATION

Neutrophil trails guide influenza-specific CD8+ T cells in the airways

(2015) K. Lim et al.   SCIENCE

Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site

(2015) Maxime Thoreau et al.   Oncotarget

Neutrophil Influx and Chemokine Production during the Early Phases of the Antitumor Response to the Vascular Disrupting Agent DMXAA (ASA404)

(2015) Liang-Chuan S. Wang et al.   NEOPLASIA

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

(2014) Antonella Sistigu et al.   NATURE MEDICINE

DMXAA Causes Tumor Site-Specific Vascular Disruption in Murine Non-Small Cell Lung Cancer, and like the Endogenous Non-Canonical Cyclic Dinucleotide STING Agonist, 2′3′-cGAMP, Induces M2 Macrophage Repolarization

(2014) Charlene M. Downey et al.   PLoS One

Using macrophage activation to augment immunotherapy of established tumours

(2013) Z G Fridlender et al.   BRITISH JOURNAL OF CANCER

The Chemotherapeutic Agent DMXAA as a Unique IRF3-Dependent Type-2 Vaccine Adjuvant

(2013) Choon Kit Tang et al.   PLoS One

5,6-Dimethylxanthenone-4-acetic Acid (DMXAA) Activates Stimulator of Interferon Gene (STING)-dependent Innate Immune Pathways and Is Regulated by Mitochondrial Membrane Potential

(2012) Daniel Prantner et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors

(2012) Hélène Salmon et al.   JOURNAL OF CLINICAL INVESTIGATION

The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents

(2010) Dietmar W. Siemann   CANCER TREATMENT REVIEWS

Temporal aspects of the action of ASA404 (vadimezan; DMXAA)

(2010) Bruce C Baguley et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-β-mediated antiviral activity in vitro and in vivo

(2010) Kari Ann Shirey et al.   JOURNAL OF LEUKOCYTE BIOLOGY

IFN-β-Dependent Inhibition of Tumor Growth by the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA)

(2008) Zachary J. Roberts et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH